Results 1 to 10 of about 15,824 (192)

Ceftazidime-avibactam [PDF]

Revista Española de Quimioterapia, 2021
Ceftazidime is a 3rd generation cephalosporin active against Pseudomonas aeruginosa. Avibactam is an inhibitor of class A, C and some class D β-lactamases. The antibacterial spectrum of ceftazidime-avibactam covers 95% of P. aeruginosa isolates and >99% of enterobacteria, including strains carrying extended-spectrum β-lactamases (ESBLs).
Matesanz, Mayra, Mensa, José
openaire   +2 more sources

Antimicrobial Resistance Profiles of Pseudomonas aeruginosa in a Korean Community Hospital: In Vitro Activity of Ceftazidime-Avibactam and Other Agents [PDF]

Polish Journal of Microbiology
The novel antibiotic ceftazidime-avibactam was introduced in Korea in 2023. This study evaluated the in vitro susceptibility of Pseudomonas aeruginosa isolates from a community-based hospital to various antibiotics, including ceftazidime-avibactam.
Lee Hyo-Jin, Cho Sung-Yeon, Lee Dong-Gun, Park Chulmin, Byun Jihyun, Chun Hye-Sun, Kim Yang Ree   +6 more
doaj   +2 more sources

In vitro Optimization of Ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae

Frontiers in Microbiology, 2021
Ceftazidime/avibactam is an important treatment option for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-Kp), however, resistance can emerge during treatment.
Yanqin Huang, Tiffany Wu, Omar Perez, Amisha P. Rana, Liang Chen, Liang Chen, Barry N. Kreiswirth, Michael J. Satlin, Zackery P. Bulman   +8 more
doaj   +1 more source

In Vitro Activities of Ceftazidime–Avibactam and Aztreonam–Avibactam at Different Inoculum Sizes of Extended-Spectrum β-Lactam-Resistant Enterobacterales Blood Isolates

Antibiotics, 2021
β-lactam–avibactam combinations have been proposed as carbapenem-sparing therapies, but little data exist on their in vitro activities in infections with high bacterial inocula.
Moonsuk Bae, Taeeun Kim, Joung Ha Park, Seongman Bae, Heungsup Sung, Mi-Na Kim, Jiwon Jung, Min Jae Kim, Sung-Han Kim, Sang-Oh Lee, Sang-Ho Choi, Yang Soo Kim, Yong Pil Chong   +12 more
doaj   +1 more source

Ceftazidime-avibactam plus metronidazole vs. meropenem in complicated intra-abdominal infections: Indian subset from RECLAIM

Journal of Infection in Developing Countries, 2022
Introduction: This study analyzes the safety and efficacy results of the Indian population subset from the RECLAIM trial investigating the non-inferiority of Ceftazidime-Avibactam (CAZ-AVI) plus metronidazole to meropenem and interprets its relevance.
Prithi Rodgers, Shweta Kamat, Charles Adhav   +2 more
doaj   +1 more source

Genetic Dissection of Antibiotic Adjuvant Activity

mBio, 2022
Small molecule adjuvants that enhance the activity of established antibiotics represent promising agents in the battle against antibiotic resistance. Adjuvants generally act by inhibiting antibiotic resistance processes, and specifying the process acted ...
J. Bailey, L. Gallagher, W. T. Barker, V. B. Hubble, J. Gasper, C. Melander, C. Manoil   +6 more
doaj   +1 more source

Repurposing Cefazolin-Avibactam for the Treatment of Drug Resistant Mycobacterium tuberculosis

Frontiers in Pharmacology, 2021
Background: While tuberculosis (TB) is curable and preventable, the most effective first-line antibiotics cannot kill multi-drug resistant (MDR) Mycobacterium tuberculosis (Mtb).
Shashikant Srivastava, Shashikant Srivastava, Shashikant Srivastava, Tawanda Gumbo, Tania Thomas   +4 more
doaj   +1 more source

Increased gene expression and copy number of mutated bla KPC lead to high-level ceftazidime/avibactam resistance in Klebsiella pneumoniae

BMC Microbiology, 2021
Background Resistance to ceftazidime-avibactam was reported, and it is important to investigate the mechanisms of ceftazidime/avibactam resistance in K. pneumoniae with mutations in bla KPC. Results We report the mutated bla KPC is not the only mechanism
Lingxiao Sun, Haibo Li, Qi Wang, Yingmei Liu, Bin Cao   +4 more
doaj   +1 more source

Detecting KPC-2 and NDM-1 Coexpression in Klebsiella pneumoniae Complex from Human and Animal Hosts in South America

Microbiology Spectrum, 2022
Reports of Gram-negative bacteria harboring multiple carbapenemase genes have increased in South America, leading to an urgent need for appropriate microbiological diagnosis.
Felipe Vásquez-Ponce, Karine Dantas, Johana Becerra, Gregory Melocco, Fernanda Esposito, Brenda Cardoso, Larissa Rodrigues, Keila Lima, Aline V. de Lima, Fábio P. Sellera, Renata Mattos, Lucas Trevisoli, Marco A. Vianello, Thais Sincero, Jose Di Conza, Eliana Vespero, Gabriel Gutkind, Jorge Sampaio, Nilton Lincopan   +18 more
doaj   +1 more source

Resistance to aztreonam-avibactam due to CTX-M-15 in the presence of penicillin-binding protein 3 with extra amino acids in Escherichia coli

Frontiers in Microbiology, 2022
Aztreonam-avibactam is a promising combination to treat carbapenem-resistant Enterobacterales including coverage for metallo-β-lactamases. Escherichia coli strains resistant to aztreonam-avibactam have emerged but resistance mechanisms remain to be ...
Ke Ma, Zhiyong Zong, Zhiyong Zong, Zhiyong Zong   +3 more
doaj   +1 more source